Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
$99.99
$97.65
$45.50
$100.00
$6.17B0.551.56 million shs107 shs
ArQule, Inc. stock logo
ARQL
ArQule
$20.00
$20.00
$3.15
$20.45
$2.42B2.495.27 million shsN/A
Biohaven Ltd. stock logo
BHVN
Biohaven
$13.90
+0.8%
$16.58
$13.75
$55.70
$1.42B0.911.29 million shs1.11 million shs
Insmed, Inc. stock logo
INSM
Insmed
$96.14
-0.8%
$81.42
$60.40
$106.83
$18.24B0.92.30 million shs1.91 million shs
uniQure N.V. stock logo
QURE
uniQure
$14.44
+0.9%
$14.54
$3.76
$19.18
$791.02M0.081.96 million shs704,160 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
ArQule, Inc. stock logo
ARQL
ArQule
0.00%0.00%0.00%0.00%0.00%
Biohaven Ltd. stock logo
BHVN
Biohaven
-5.60%-2.13%-18.72%-16.45%-59.47%
Insmed, Inc. stock logo
INSM
Insmed
-1.57%-3.67%+31.69%+49.22%+38.50%
uniQure N.V. stock logo
QURE
uniQure
-1.21%+2.65%-17.14%+71.58%+272.66%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
ArQule, Inc. stock logo
ARQL
ArQule
N/AN/AN/AN/AN/AN/AN/AN/A
Biohaven Ltd. stock logo
BHVN
Biohaven
3.188 of 5 stars
4.51.00.00.01.82.50.6
Insmed, Inc. stock logo
INSM
Insmed
4.5613 of 5 stars
3.54.00.04.33.41.70.6
uniQure N.V. stock logo
QURE
uniQure
2.1195 of 5 stars
3.51.00.00.01.52.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
0.00
N/AN/AN/A
ArQule, Inc. stock logo
ARQL
ArQule
0.00
N/AN/AN/A
Biohaven Ltd. stock logo
BHVN
Biohaven
3.07
Buy$58.46320.59% Upside
Insmed, Inc. stock logo
INSM
Insmed
3.00
Buy$108.0712.41% Upside
uniQure N.V. stock logo
QURE
uniQure
2.91
Moderate Buy$37.82161.90% Upside

Current Analyst Ratings Breakdown

Latest INSM, QURE, ARNA, ARQL, and BHVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Insmed, Inc. stock logo
INSM
Insmed
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$90.00 ➝ $111.00
6/18/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$68.00 ➝ $55.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$100.00 ➝ $112.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$96.00 ➝ $110.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$99.00 ➝ $106.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$90.00 ➝ $102.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$107.00 ➝ $119.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$94.00 ➝ $109.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$90.00 ➝ $120.00
6/10/2025
Insmed, Inc. stock logo
INSM
Insmed
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
6/10/2025
Insmed, Inc. stock logo
INSM
Insmed
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
$50K123,305.67N/AN/A$10.94 per share9.14
ArQule, Inc. stock logo
ARQL
ArQule
$25.76M93.85N/AN/A$0.72 per share27.78
Biohaven Ltd. stock logo
BHVN
Biohaven
N/AN/AN/AN/A$4.19 per shareN/A
Insmed, Inc. stock logo
INSM
Insmed
$381.03M47.87N/AN/A$1.60 per share60.09
uniQure N.V. stock logo
QURE
uniQure
$27.12M29.17N/AN/A($0.14) per share-103.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
-$616.43M-$10.13N/AN/AN/AN/A-69.83%-62.35%N/A
ArQule, Inc. stock logo
ARQL
ArQule
-$15.48M-$0.16N/AN/AN/A-805.61%-33.10%-26.87%N/A
Biohaven Ltd. stock logo
BHVN
Biohaven
-$846.42M-$9.36N/AN/AN/AN/A-257.07%-164.01%8/5/2025 (Estimated)
Insmed, Inc. stock logo
INSM
Insmed
-$913.77M-$5.95N/AN/AN/A-265.93%-446.98%-52.70%8/6/2025 (Estimated)
uniQure N.V. stock logo
QURE
uniQure
-$239.56M-$4.39N/AN/AN/A-1,077.05%-483.87%-34.28%8/7/2025 (Estimated)

Latest INSM, QURE, ARNA, ARQL, and BHVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Biohaven Ltd. stock logo
BHVN
Biohaven
-$1.67-$2.17-$0.50-$2.17$1.25 millionN/A
5/9/2025Q1 2025
uniQure N.V. stock logo
QURE
uniQure
-$1.07-$0.82+$0.25-$0.82$5.93 million$1.57 million
5/8/2025Q1 2025
Insmed, Inc. stock logo
INSM
Insmed
-$1.36-$1.42-$0.06-$1.42$91.63 million$92.82 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
N/AN/AN/AN/AN/A
ArQule, Inc. stock logo
ARQL
ArQule
N/AN/AN/AN/AN/A
Biohaven Ltd. stock logo
BHVN
Biohaven
N/AN/AN/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
uniQure N.V. stock logo
QURE
uniQure
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
0.05
8.59
8.59
ArQule, Inc. stock logo
ARQL
ArQule
0.08
8.27
8.27
Biohaven Ltd. stock logo
BHVN
Biohaven
N/A
2.33
2.33
Insmed, Inc. stock logo
INSM
Insmed
11.38
5.86
5.44
uniQure N.V. stock logo
QURE
uniQure
1.53
11.99
11.99

Institutional Ownership

CompanyInstitutional Ownership
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
83.77%
ArQule, Inc. stock logo
ARQL
ArQule
74.63%
Biohaven Ltd. stock logo
BHVN
Biohaven
88.78%
Insmed, Inc. stock logo
INSM
Insmed
N/A
uniQure N.V. stock logo
QURE
uniQure
78.83%

Insider Ownership

CompanyInsider Ownership
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
2.41%
ArQule, Inc. stock logo
ARQL
ArQule
13.80%
Biohaven Ltd. stock logo
BHVN
Biohaven
14.60%
Insmed, Inc. stock logo
INSM
Insmed
3.00%
uniQure N.V. stock logo
QURE
uniQure
4.79%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
44861.66 million60.17 millionOptionable
ArQule, Inc. stock logo
ARQL
ArQule
36120.87 millionN/AOptionable
Biohaven Ltd. stock logo
BHVN
Biohaven
239102.11 million87.21 millionOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,271189.71 million184.02 millionOptionable
uniQure N.V. stock logo
QURE
uniQure
50054.78 million52.15 millionOptionable

Recent News About These Companies

uniQure: Price And Value Have Caught Up

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Arena Pharmaceuticals stock logo

Arena Pharmaceuticals NASDAQ:ARNA

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

ArQule stock logo

ArQule NASDAQ:ARQL

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Its pipeline also comprises ARQ 75, a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase, and tensin homolog loss mutations. In addition, the company's pipeline includes Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma in patients with FGFR2 fusions. ArQule, Inc. has license agreements with Basilea Pharmaceutica Limited and Roivant Sciences Ltd. The company was founded in 1993 and is headquartered in Burlington, Massachusetts.

Biohaven stock logo

Biohaven NYSE:BHVN

$13.90 +0.11 (+0.80%)
Closing price 03:59 PM Eastern
Extended Trading
$13.99 +0.09 (+0.65%)
As of 06:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Insmed stock logo

Insmed NASDAQ:INSM

$96.14 -0.81 (-0.84%)
Closing price 04:00 PM Eastern
Extended Trading
$98.88 +2.75 (+2.86%)
As of 06:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

uniQure stock logo

uniQure NASDAQ:QURE

$14.44 +0.13 (+0.91%)
Closing price 04:00 PM Eastern
Extended Trading
$14.56 +0.12 (+0.83%)
As of 05:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.